Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Central Diabetes Insipidus

Endocrine & Hormonal

Central Diabetes Insipidus (CDI) Clinical Trials

Also called CDI, vasopressin deficiency, neurogenic DI, arginine vasopressin deficiency, AVP-D

Central diabetes insipidus (CDI) results from deficiency of arginine vasopressin (antidiuretic hormone, ADH) due to dysfunction of the hypothalamic-pituitary system. Causes include pituitary or hypothalamic tumors (craniopharyngiomas, germinomas, adenomas), pituitary surgery or radiation therapy, traumatic brain injury, infections (meningitis, encephalitis, tuberculous meningitis), autoimmune hypophysitis, or idiopathic forms accounting for 30-50% of cases.

In plain words, central diabetes insipidus happens when the brain does not make enough of a hormone that helps the body hold on to water. As a result, the body makes large amounts of watery urine and the person feels very thirsty.

Get an email when new Central Diabetes Insipidus trials open or the FDA decides. Get alerts

Central Diabetes Insipidus

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 4 studies with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines1

Desmoda

Central Diabetes Insipidus has 1 FDA-approved medicine, 10 open or active clinical trials (9 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Central Diabetes Insipidus

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Central Diabetes Insipidus

Congenital forms result from genetic mutations affecting vasopressin synthesis (AVP gene mutations, DIDMOAD syndrome). Without vasopressin, the kidneys lose the ability to concentrate urine and reabsorb water, resulting in massive polyuria (5-20+ liters daily in untreated patients) and intense polydipsia.

Keep reading about Central Diabetes Insipidus

Severe dehydration and hypernatremia (sodium >150mEq/L) develop rapidly if fluid intake cannot match urine output. Diagnosis requires simultaneous assessment of serum osmolality (>300 mOsm/kg), urine osmolality (<300 mOsm/kg), and vasopressin levels (inappropriately low). Water deprivation testing and desmopressin response confirm the diagnosis and distinguish central from nephrogenic DI.

What are the symptoms of Central Diabetes Insipidus?

These are common symptoms of Central Diabetes Insipidus, and how strong they are varies from person to person.

  • Severe polydipsia (excessive thirst)
  • Polyuria (excessive urination) with dilute urine
  • Dehydration and hypernatremia if intake inadequate
  • Nocturia and enuresis in children
  • Difficulty concentrating dilute urine
  • Symptoms worse with stress or fever

Who gets Central Diabetes Insipidus?

CDI can present at any age depending on the underlying cause. Congenital forms present in infancy with severe polyuria and failure to thrive if undiagnosed. Acquired forms can present acutely following pituitary surgery, head trauma, or infection, or insidiously with progressive disease. Idiopathic CDI may present in adolescence or adulthood without identified cause.

The condition affects males and females equally across all ethnic groups. Geographic clustering occurs in families with genetic forms (DIDMOAD syndrome, AVP mutations). Autosomal recessive and dominant inheritance patterns have been described in familial forms. Approximately 50% of cases are idiopathic with no identifiable structural or genetic cause.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Central Diabetes Insipidus?

There is currently 1 FDA-approved medication for Central Diabetes Insipidus.

Desmoda
desmopressin acetate oral solution
Eton Pharmaceuticals, Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Central Diabetes Insipidus

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Central Diabetes Insipidus resources

Reputable organizations and medical references for learning more about Central Diabetes Insipidus, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Central Diabetes Insipidus

Use this Central Diabetes Insipidus clinical trial finder to see the 9 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. All of them test a treatment. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

10 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialEarly Phase 1Recently updatedNCT07568509

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

Intervention: Norethindrone Acetate-Ethinyl Estradiol

Sponsor: Massachusetts General Hospital

An open-labeled, interventional pilot trial, 10 youth with AVP-D and 10 PD matched for age, sex, and BMI will be recruited from Pediatric Endocrinology and Neuroendocrinology at Massachusetts General Hospital and in the community. This study tests the hypothesis that oral estroge...

Ages 7 Years to 21 Years1 location
Started Aug 2026Updated 3 weeks agoEst. Apr 2027 (~5 months)
RecruitingTreatment trialPhase 1Recently updatedNCT04789148

Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency

Intervention: Intranasal Oxytocin (IN-OXT) 6 IU single dose, Intranasal Oxytocin (IN-OXT) 6 IU repeat dose, Placebo repeat dose, Intranasal Oxytocin (IN-OXT) 24 IU single dose, Placebo single dose

Sponsor: Elizabeth Austen Lawson · Tonix Pharmaceuticals, Inc.

This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depres...

Ages 18 Years+1 location
Started Sep 2025Updated 3 weeks agoEst. Jun 2027 (~7 months)
RecruitingTreatment trialPhase 2Recently updatedNCT06368817

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Intervention: 3-Dimensional Conformal Proton Radiation Therapy, 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Carboplatin, Etoposide, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Questionnaire Administration, Surgical Procedure

Sponsor: Children's Oncology Group

This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin & Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and s...

Ages 3 Years to 29 Years
Started Oct 2024Updated 2 months agoEst. Nov 2033 (~6y 11m)
RecruitingTreatment trialUpdated a few months agoNCT07361263

Plasma Oxytocin Response to Oral Estrogens in Healthy Controls and AVP-Deficiency

Intervention: estradiol valerate, esthinylestradiol

Sponsor: University Hospital, Basel, Switzerland

The PHOENIX study aims to investigate whether oral estradiol valerate (EV) and ethinylestradiol (EE) can stimulate oxytocin (OXT) and neurophysin-1 (NP-1) release in humans. The goal is to assess their potential as a safe diagnostic stimulation test for oxytocin deficiency, parti...

Ages 18 Years to 50 Years1 location
Started Jan 2026Updated 3 months agoEst. Feb 2027 (~3 months)
RecruitingTreatment trialUpdated a few months agoNCT07569861

Copeptin Measurement After Mannitol and Hypertonic Saline for the Diagnosis of Polyuria-polydipsia Syndrome

Intervention: Mannitol, Hypertonic Saline

Sponsor: University Hospital, Basel, Switzerland

The aim of this study is to evaluate whether a new test using mannitol infusion can diagnose the cause of polyuria-polydipsia syndrome as accurately as the current standard test (hypertonic saline infusion) and to compare which test patients prefer. The goal is to identify a simp...

Ages 18 Years+1 location
Started Jun 2026Updated 5 months agoEst. Jun 2030 (~3y 7m)
Find Central Diabetes Insipidus trials near you, ranked by distance →
Active trial locations79 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+71 more

Trial Pipeline

Jan 2024 to Nov 2031
2025
2027
2029
2031
now
Early Phase 1
Phase 1
Phase 2
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Central Diabetes Insipidus trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Central Diabetes Insipidus foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Central Diabetes Insipidus patient communities

Facebook groups, Reddit communities and YouTube channels where Central Diabetes Insipidus patients, caregivers and advocacy groups talk.

Questions people ask about Central Diabetes Insipidus